Irinotecan (Conventional) and Neratinib Maleate
Determining the interaction of Irinotecan (Conventional) and Neratinib Maleate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with neratinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter, such as dabigatran, rosuvastatin, sulfasazine, and topotecan. The proposed mechanisms, based on in vitro data, is decreased clearance due to neratinib-mediated inhibition of BCRP transport protein. There are no clinical data regarding the use of neratinib with BCRP substrates. MANAGEMENT: Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever neratinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects. References Cerner Multum, Inc. "Australian Product Information." O 0
Professional:MONITOR: Coadministration with neratinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter, such as dabigatran, rosuvastatin, sulfasazine, and topotecan. The proposed mechanisms, based on in vitro data, is decreased clearance due to neratinib-mediated inhibition of BCRP transport protein. There are no clinical data regarding the use of neratinib with BCRP substrates.
MANAGEMENT: Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever neratinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: irinotecan
Brand name: Camptosar
Synonyms: Irinotecan
Generic Name: neratinib
Brand name: Nerlynx
Synonyms: Neratinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Irinotecan (Conventional)-Nerlynx
- Irinotecan (Conventional)-Neruo-K-500
- Irinotecan (Conventional)-Nesacaine
- Irinotecan (Conventional)-Nesacaine-MPF
- Irinotecan (Conventional)-Nesina
- Irinotecan (Conventional)-Nesiritide
- Neratinib Maleate-Irinotecan Hydrochloride
- Neratinib Maleate-Irinotecan Intravenous
- Neratinib Maleate-Irinotecan liposomal
- Neratinib Maleate-Irinotecan liposome Intravenous
- Neratinib Maleate-Iron 100/C
- Neratinib Maleate-Iron 21/7